The PD-1 and PD-L1 inhibitor market has witnessed a surge in investment and funding in recent years, owing to the promising potential of these immunotherapies in cancer treatment. PD-1 and PD-L1 inhibitors have shown remarkable efficacy in certain types of cancer, revolutionizing the oncology landscape. As a result, pharmaceutical companies, biotech startups, and research institutions are increasingly directing their resources toward advancing research, development, and commercialization of ... Read more
